Skip to main content
. 2018 Jan 22;9(2):68. doi: 10.1038/s41419-017-0075-7

Fig. 7. A proposed model of niclosamide activity against imatinib-resistant T315I mutation.

Fig. 7

Niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1, resulting in the impairing of BCR-ABL signaling transduction